This product is a CRISPR/Cas9-edited polyclonal ARID4A knockout cell population derived from HAP1 cells, a human near-haploid chronic myeloid leukemia model. The polyclonal nature ensures representation of multiple knockout alleles, avoiding clonal artifacts. The cells provide a loss-of-function model to study ARID4A-dependent chromatin remodeling and transcriptional repression.
HAP1 cells originate from the KBM-7 chronic myeloid leukemia patient line and exhibit a near-haploid karyotype, making them a premier haploid genetic screening platform. Their stable, near-haploid genome simplifies genotype-phenotype correlation and enhances the sensitivity of functional genomics assays, particularly for tumor suppressor gene studies.
ARID4A functions as a key scaffold that assembles the SIN3A?CHDAC corepressor complex, including SIN3A, HDAC1, HDAC2, SAP30, and BRMS1, and facilitates its recruitment to chromatin via interaction with RB1. This complex catalyzes histone deacetylation, leading to transcriptional repression of pro-proliferative and anti-apoptotic targets such as CDKN1A (p21), BCL2 family members, and cyclin-dependent kinase inhibitors. ARID4A activity is regulated by upstream signals including retinoic acid and p53, linking it to growth-suppressive and differentiation pathways.
In the HAP1 background, disrupting ARID4A is expected to derepress key cell cycle and survival genes, potentially altering proliferation, apoptosis, and genomic stability. The haploid genetic context allows clear attribution of phenotypic changes to ARID4A loss, providing an ideal system for dissecting tumor suppressor networks and epigenetic regulatory mechanisms without the confounding effects of a diploid genome.
This polyclonal knockout cell pool is suited for a wide range of applications, including functional genomics screens using RNA-seq and ChIP-qPCR to map ARID4A-dependent transcriptional and epigenetic landscapes, cell cycle and apoptosis assays to investigate growth control, and HDAC activity assays for epigenetic drug profiling. Co-immunoprecipitation experiments can validate interactions with SIN3A?CHDAC components, while drug sensitivity testing can explore synthetic lethal interactions in ARID4A-deficient contexts. For additional details, please contact Ascent Research.
